A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 233 participants.
Also called NCT05563246
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 233 participants
- Sponsor
- Registry
-
NCT05563246 -
2022-501466-21-00
-
- Other papers using this trial's data
- Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Brazil, China, Germany, Hungary, Japan, Netherlands
- Registry status
- Completed
Technical summary
Registry record NCT05563246. Randomized; double masking; primary purpose treatment. Start 2022-11-24 (actual); primary completion 2024-03-14 (actual). Results posted on 2025-03-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
- Acronym
- KRAKEN
- Condition
- Lipoprotein Disorder
- Intervention (Drug)
- LY3473329
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct05563246- Content hash
7b7859a19f1fa03d0d5cac59ef401675053a218287a26b6d811297367117d62f